Jurij Stekar

1.2k total citations
25 papers, 1.0k citations indexed

About

Jurij Stekar is a scholar working on Organic Chemistry, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Jurij Stekar has authored 25 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Organic Chemistry, 7 papers in Molecular Biology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Jurij Stekar's work include Chemotherapy-induced organ toxicity mitigation (6 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Sulfur Compounds in Biology (4 papers). Jurij Stekar is often cited by papers focused on Chemotherapy-induced organ toxicity mitigation (6 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Sulfur Compounds in Biology (4 papers). Jurij Stekar collaborates with scholars based in Germany, Japan and Netherlands. Jurij Stekar's co-authors include N Brock, Jörg Pohl, J. Pohl, W Scheef, Bernhard Kutscher, Peter Hilgard, Ulf Niemeyer, P. Hilgard, R. Voegeli and J. Engel and has published in prestigious journals such as Cellular and Molecular Life Sciences, European Journal of Cancer and Cancer Treatment Reviews.

In The Last Decade

Jurij Stekar

25 papers receiving 924 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jurij Stekar Germany 14 400 307 263 130 102 25 1.0k
Susan M. Ludeman United States 20 593 1.5× 226 0.7× 387 1.5× 215 1.7× 193 1.9× 51 1.4k
Robert H. Earhart United States 19 354 0.9× 145 0.5× 469 1.8× 34 0.3× 80 0.8× 45 1.1k
K D Tutsch United States 17 492 1.2× 161 0.5× 544 2.1× 47 0.4× 55 0.5× 22 1.4k
O. Michael Colvin United States 15 337 0.8× 73 0.2× 197 0.7× 81 0.6× 98 1.0× 23 790
M.G. Donelli Italy 19 305 0.8× 95 0.3× 474 1.8× 80 0.6× 43 0.4× 60 1.1k
Franz A. Schmid United States 14 296 0.7× 76 0.2× 167 0.6× 92 0.7× 101 1.0× 53 669
Marlene A. Bunni United States 21 535 1.3× 75 0.2× 333 1.3× 205 1.6× 40 0.4× 46 1.2k
W R Laster United States 17 397 1.0× 77 0.3× 317 1.2× 61 0.5× 175 1.7× 42 957
A. H. Blair Canada 18 468 1.2× 224 0.7× 154 0.6× 29 0.2× 69 0.7× 31 1.1k
I Wodinsky United States 15 492 1.2× 46 0.1× 331 1.3× 90 0.7× 100 1.0× 69 979

Countries citing papers authored by Jurij Stekar

Since Specialization
Citations

This map shows the geographic impact of Jurij Stekar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jurij Stekar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jurij Stekar more than expected).

Fields of papers citing papers by Jurij Stekar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jurij Stekar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jurij Stekar. The network helps show where Jurij Stekar may publish in the future.

Co-authorship network of co-authors of Jurij Stekar

This figure shows the co-authorship network connecting the top 25 collaborators of Jurij Stekar. A scholar is included among the top collaborators of Jurij Stekar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jurij Stekar. Jurij Stekar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hilgard, Peter, Jurij Stekar, R. Voegeli, & Johannes H. Harleman. (2015). Experimental Therapeutic Studies with Miltefosine in Rats and Mice. Progress in tumor research. 34. 116–130. 3 indexed citations
2.
Hilgard, P., et al.. (1997). D-21266, a new heterocyclic alkylphospholipid with antitumour activity. European Journal of Cancer. 33(3). 442–446. 119 indexed citations
3.
Hilgard, P., et al.. (1996). Heterocyclic Alkylphospholipids with an Improved Therapeutic Range. Advances in experimental medicine and biology. 416. 157–164. 9 indexed citations
4.
Stekar, Jurij, et al.. (1995). Synthese sowie Antitumorwirksamkeit und Verträglichkeit im Tierexperiment von elementhomologen Phospholipiden. Angewandte Chemie. 107(2). 195–197. 4 indexed citations
5.
Stekar, Jurij, et al.. (1995). Synthesis, Antitumor Activity, and Tolerability of Phospholipids Containing Nitrogen Homologues. Angewandte Chemie International Edition in English. 34(2). 238–240. 29 indexed citations
6.
Stekar, Jurij, Peter Hilgard, R. Voegeli, et al.. (1993). Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133. Cancer Chemotherapy and Pharmacology. 32(6). 437–444. 27 indexed citations
7.
8.
Stekar, Jurij, et al.. (1990). Protection from ifosfamide-induced alopecia by topical thiols in young rats. Cancer Chemotherapy and Pharmacology. 25(4). 306–307. 3 indexed citations
9.
Brock, N, et al.. (1989). Experimental investigations into the carcinogenic effect of antitumor and immunosuppressive agents. Journal of Cancer Research and Clinical Oncology. 115(4). 309–328. 2 indexed citations
10.
Pohl, J., Jurij Stekar, & P. Hilgard. (1989). Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication.. PubMed. 39(6). 704–5. 14 indexed citations
11.
Hilgard, Peter, Jurij Stekar, R. Voegeli, et al.. (1988). Characterization of the antitumor activity of hexadecylphosphocholine (D 18506). European Journal of Cancer and Clinical Oncology. 24(9). 1457–1461. 92 indexed citations
12.
Hilgard, Peter, Jörg Pohl, Jurij Stekar, & R. Voegeli. (1985). Oxazaphosphorines as biological response modifiers-experimental and clinical perspectives. Cancer Treatment Reviews. 12(3). 155–162. 31 indexed citations
13.
Ormstad, Kari, et al.. (1983). Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat.. PubMed. 43(1). 333–8. 72 indexed citations
14.
Brock, N, J. Pohl, & Jurij Stekar. (1981). Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds. Journal of Cancer Research and Clinical Oncology. 100(3). 311–320. 53 indexed citations
15.
Stekar, Jurij, et al.. (1980). Induction of lung tumours in rats by i.v. injection of N-methyl-N′-nitro-N-nitrosoguanidine. European Journal of Cancer (1965). 16(3). 395–400. 3 indexed citations
16.
Brock, N, et al.. (1979). Antidot gegen urotoxische Wirkungen der Oxazaphosphorin-Derivate Cyclophosphamid, Ifosfamid und Trofosfamid. Die Naturwissenschaften. 66(1). 60–61. 28 indexed citations
17.
Stekar, Jurij. (1977). Pulmotropic carcinogenic activity of N-methyl-N-nitrosopropionamide. European Journal of Cancer (1965). 13(10). 1183–1189. 2 indexed citations
18.
Stekar, Jurij. (1976). [Chemotherapeutic activity of ifosfamide in 6 different isologously transplanted experimental tumours of BD-rats (author's transl)].. PubMed. 26(10). 1793–7. 4 indexed citations
19.
Druckrey, H., et al.. (1973). Carcinogene Wirkung von �thoxy-diazenium-Salzen (0-�thyl-dialkylnitrosimmonium-Salzen) an Ratten. Journal of Cancer Research and Clinical Oncology. 80(1). 17–26. 1 indexed citations
20.
Druckrey, H., et al.. (1968). Transplacentar induction of neurogenic malignomas by 1,2-diethyl-hydrazine, azo-, and azoxy-ethane in rats. Cellular and Molecular Life Sciences. 24(6). 561–562. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan M. Ludeman Breakdown of academic impact, for papers by Robert H. Earhart Breakdown of academic impact, for papers by K D Tutsch Breakdown of academic impact, for papers by O. Michael Colvin Breakdown of academic impact, for papers by M.G. Donelli Breakdown of academic impact, for papers by Franz A. Schmid Breakdown of academic impact, for papers by Marlene A. Bunni Breakdown of academic impact, for papers by W R Laster Breakdown of academic impact, for papers by A. H. Blair Breakdown of academic impact, for papers by I Wodinsky
Rankless by CCL
2026